Track topics on Twitter Track topics that are important to you
Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict CR to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).
(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.
US-based Celldex Therapeutics has started an open-label, Phase I/II safety and tolerability trial evaluating the investigational combination of varlilumab and sunitinib (Sutent) in patients with metas...
Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To ...
Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate. We assessed ...
Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is ...
Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated wit...
Real world data (RWD) are increasingly used to inform drug reimbursement decisions, but it is unclear how well outcomes from real world studies compare to those of clinical trials. This systematic rev...